Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Clinical genitourinary cancer - 1 Oct 2018

Gao Xin, Jegede Opeyemi, Gray Connor, Catalano Paul J, Novak Jesse, Kwiatkowski David J, McKay Rana R, George Daniel J, Choueiri Toni K, McDermott David F, Signoretti Sabina, Bhatt Rupal S

Abstract excerpt

INTRODUCTION: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus. PATIENTS AND METHODS: An open-label,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biopsy, Needle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Everolimus

Share to High-Throughput Nucleotide Sequencing

Share to Kidney Neoplasms

Share to Neoplasm Metastasis

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 29754934
DOI: 10.1016/j.clgc.2018.04.001
PMCID: PMC6175670

Genes

ATM
PBRM1
SETD2
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.PMID 29754934Read ↗

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.Semantic proximity Read ↗

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Semantic proximity Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Semantic proximity Read ↗

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.Semantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.Semantic proximity Read ↗

Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.